Ann: Preliminary Final Report, page-3

The Reddys situation sounds as tricky as ever, but top line sales aren't bad.

"Included in the fondaparinux revenue for the year is an amount of US$1.15 million for the June quarter profit share. This amount is comprised of the June quarter draft net profit share result of US$1.64 million, less a deduction of $0.49 million for a prior year sales return claim (US$0.22 million) and a provision adjustment for potential future sales returns (US$0.27 million). The provision adjustment of $0.27 million has been made as a result of Dr. Reddy’s advising that an additional provision of US$1.1m is required to cover potential future sales returns, which they are proposing to recoup over four quarters commencing with the quarter ended 30 June 2015. Whilst the Company has deducted this amount for the purposes of finalising the financial result for the year ended 30 June 2015, the Company is currently disputing the methodology used by Dr Reddy’s to estimate the sales return provision, and accordingly the proposed additional charge. The outcome of this dispute is unknown at this time."